• Explore /
  • Poster
  • / Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.

Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.

Abstract Poster

Authors

null

Yves Fradet

CHU de Québec - Université Laval, Québec City, QC, Canada

Yves Fradet , Joaquim Bellmunt , Ronald De Wit , David J. Vaughn , Jae-Lyun Lee , Lawrence Fong , Nicholas J. Vogelzang , Miguel A. Climent , Daniel Peter Petrylak , Toni K. Choueiri , Andrea Necchi , Winald R. Gerritsen , Howard Gurney , David I. Quinn , Stephane Culine , Cora N. Sternberg , Kijoeng Nam , Tara L. Frenkl , Rodolfo F. Perini , Dean F. Bajorin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT02256436

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4521)

DOI

10.1200/JCO.2018.36.15_suppl.4521

Abstract #

4521

Poster Bd #

347

Abstract Disclosures

Similar Posters

First Author: Joaquim Bellmunt

First Author: Joaquim Bellmunt

First Author: Brian M. Slomovitz

First Author: Peter H. O'Donnell